Targeting ß-Catenin in Mpnsts

Total Page:16

File Type:pdf, Size:1020Kb

Targeting ß-Catenin in Mpnsts Thesis: Targeting β-catenin in MPNSTs. Jed Kendall August 8th, 2016 Previous Degree: B.S. from Brigham Young University Degree to be conferred: Doctorate of Philosophy Department: Molecular and Developmental Biology Committee Chair: Nancy Ratner Abstract MPNSTs are a highly invasive soft tissue sarcoma that arises from aberrantly regulated Schwann cells/Schwann cell precursors. Fifty percent of MPNSTs originate in patients with Neurofibromatosis type 1, an autosomal dominant disease that affects 1:3500 people, and the other fifty percent are sporadic in origin. Curative drug treatments are lacking due to MPNSTs high resistance to chemotherapy. The combination of MPNST’s invasive nature and ability to resist chemotherapy results in a dismal 5-year survival rate Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that are a major cause of mortality of Neurofibromatosis type 1 (NF1) patients. MPNST patients have few therapeutic options available and only complete surgical resection can be curative. MPNST formation and survival are dependent on activated β- catenin signaling. The goal of my work is to identify novel genes important in MPSNT progression and survival and also to screen any developed anti cancer agents against MPNST cell lines. With this approach we can identify readily available therapeutics and also identify potential therapeutics of the future. CK2 is a known oncogenic kinase in diverse types of cancer through maintaining. Often times CK2 maintains oncogenic phenotypes through stabilizing β-catenin, which is a critical factor for MPNST survival. We found that CK2α is over expressed in MPNSTs and is critical for maintaining cell survival, as the CK2 inhibitor, CX-4945 (Silmitasertib), and shRNA targeting CK2α in vitro each significantly reduced MPNST cell viability. These effects were preceded by loss of critical signaling 2 pathways in MPNSTs, including destabilization of β-catenin and TCF-8. CX-4945 administration in vivo slowed tumor growth and extended survival time. We conclude that CK2 inhibition is a promising approach to blocking β-catenin in MPNST cells, although combinatorial therapies may be required for maximal efficacy. To find potential therapeutic targets we identified genes critical for MPNST cell survival. We used microarray analysis, stringent selection criteria, and shRNA knock down. Through these methods we identified PITX2 as a critical survival gene specific to MPNST cells. Knocking down PITX2 leads to apoptosis in MPNST cells. We discovered a novel relationship between PITX2 expression and β-Catenin protein stability. Through microarray analysis of PITX2 shRNA treated MPNST cells as compared to controls we have identified NLK, FZD6, and GAS2 as genes differentially regulated by PITX2 expression, containing bicoid response elements within the promoter, and implicate β-Catenin signaling. Furthermore, we identified GAS2 as a mechanism used by MPNSTs to stabilize β-catenin. 3 4 Preface The work contained in this thesis is published or is in preparation for publication. 1. Kendall JJ, Katherine CE, Patel AV, Rizvi TA, Largaespada DA, Ratner N. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β- catenin. Oncotarget. 2014 July 2. Kendall JJ, Patel AV, Choi K, Ratner N. PITX2 over-expression is critical for MPNST survival and promotes β-catenin protein stability. Manuscript in preparation. 5 Acknowledgments Through the course of my dissertation studies I have been graced with assistance and friendship of many colleagues. I would first like to thank Nancy Ratner for building a successful and well-funded lab. I have been the benefactor of her tremendous success. Nancy has imparted an abundance of wisdom and guidance to many, including me, through the years. I will always be grateful to Nancy for allowing me to pursue topics about which I am most passionate. The topics in retrospect are not so important; rather the refinement of thought from my own trial and error is by far and away the greatest skill that I will take away from my years as a PhD student. Outside of scientific accolades and above all else Nancy is a good person. I would like to thank my thesis committee, Dr. Aaron Zorn, Dr. Brian Gebellein, Dr. Lionel Chow, and Dr. David Largaespada. Each member of my committee has given valuable feedback for the betterment of my projects. Additionally, my committee has challenged me as a scientist and encouraged me to think outside of the box that often traps me. Additionally, I would like to thank the Molecular and Developmental and MSTP program for their support. Through the good and bad times I have had the support and friendship of many Ratner lab members. Since Ami Patel had to endure the brunt of my naïve ideas during my early years she definitely deserves the most credit. Ami, Preeti, and Tilat all have become my good friends and I will miss each of you. Kwangmin, I greatly appreciate your willingness to run a thousand different bioinformatics analyses that have been integral in forming working hypotheses. I would like to 6 thank Lindsey Aschlbacher-Smith, Katie Chaney, Jianqiang Wu and Josh Pressler for creating a fun and productive work environment. I would also like to thank Meghan Brundage for taking me under her wing when I was a new arrival. Finally, I would like to thank all of my family members. To my mom, dad and grandparents thank you for a wonderful life and magical childhood. Each of you have made tremendous sacrifices on my behalf. Any achievements that I happen to stumble upon are to your credit. Most of all, I would like to thank my lovely wife. She has been the source of my greatest happiness. From our move to Cincinnati where we purchased our first home, to raising our two beautiful children, thank you for all your love and support. 7 Table of Contents ABSTRACT ................................................................................................................................................................... 2 CHAPTER 1: ETIOLOGY, PATHWAYS, AND THERAPEUTICS OF MPNSTS ........................... 12 1.1 THE ETIOLOGY OF MPNSTS ......................................................................................................................... 12 1.2 FROM BENIGN TO MALIGNANT .................................................................................................................... 14 1.3 MPNST OUTCOMES AND TREATMENT ...................................................................................................... 15 1.4 THERAPEUTIC ADVANCEMENTS IN MPNSTS PAST AND PRESENT. ....................................................... 16 1.5 Β-CATENIN AS A POTENTIAL THERAPEUTIC TARGET IN MPNSTS ........................................................ 19 1.5.1. Canonical WNT signaling cascade ................................................................................................. 19 1.5.2 Pathogenesis of β-catenin signaling in MPNSTS ....................................................................... 21 1.5.3 WNT signaling therapeutics .............................................................................................................. 23 CHAPTER 2: CK2 AS AN ONCOTARGET ......................................................................................... 24 2.1 INTRODUCTION TO CK2 ................................................................................................................................. 24 2.2 CK2 AND DNA DAMAGE REPAIR ................................................................................................................. 26 2.3 CK2 AND CELL CYCLE PROGRESSION ........................................................................................................... 28 2.4 CK2 AND CELL DEATH/APOPTOSIS ............................................................................................................ 29 2.5 CK2 AND CANCER ........................................................................................................................................... 30 2.6 CROSS TALK BETWEEN CK2 AND PRO-SURVIVAL/PROLIFERATIVE PATHWAYS. ................................ 32 2.6.1 NF-κB and CK2 ......................................................................................................................................... 32 2.6.2 PI3K/AKT and CK2 ................................................................................................................................. 32 2.6.3 CK2 and β-catenin .................................................................................................................................. 34 2.8 RESULTS ............................................................................................................................................................ 38 2.8.1 CK2 is overexpressed in MPNSTs ...................................................................................................... 38 2.8.2 CK2 inhibition induces cell death and cell cycle arrest in MPNSTs in vitro. ................. 38 2.8.3 CK2 regulates β-catenin protein stability in MPNSTs in vitro. ........................................... 39 2.8.4 CK2 regulates TCF8 and other survival pathways in MPNSTs in vitro. .......................... 40 2.8.5 CX-4945 slows tumor growth in vivo ............................................................................................. 41 2.8.6 MPNST treatment with CX-4945 in combination with PD0325901 ................................. 42 2.9 DISCUSSION, IMPLICATIONS, AND LIMITATIONS ......................................................................................
Recommended publications
  • Supplementary Figures
    Mena regulates the LINC complex to control actin–nuclear lamina associations, trans-nuclear membrane signalling and cancer gene expression Frederic Li Mow Chee!, Bruno Beernaert!, Alexander Loftus!, Yatendra Kumar", Billie G. C. Griffith!, Jimi C. Wills!, Ann P. Wheeler#, J. Douglas Armstrong$, Maddy Parsons%, Irene M. Leigh,(, Charlotte M. Proby&, Alex von Kriegsheim!, Wendy A. Bickmore", Margaret C. Frame,* & Adam Byron,* Supplementary Information Supplementary Figure 1 Supplementary Figure 2 Supplementary Figure 3 Supplementary Table 1 Supplementary Table 2 Supplementary Table 3 Supplementary Table 4 !Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH< =XR, UK. "MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH< =XU, UK. #Advanced Imaging Resource, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH< =XU, UK. $Simons Initiative for the Developing Brain, School of Informatics, University of Edinburgh, Edinburgh EHH IYL, UK. %Randall Centre for Cell and Molecular Biophysics, King’s College London, London SEM MUL, UK. &Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee DD <HN, UK. 'Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EM =AT, UK. *email: [email protected] or [email protected] 1 a cSCC IAC correlation b cSCC IAC pathways c Core adhesome network ENAH −log10(q) MACF1 CSRP1 Met1 Met4 0 5 10 + + CORO2A Integrin signalling + CFL1 pathway PRNP ILK + HSPB1 PALLD PPFIA1 TES RDX Cytoskeletal regulation + VASP + + ARPC2 by Rho GTPase PPP2CA + Met1 + LASP1 MYH9 + VIM TUBA4A Huntington ITGA3 + disease ITGB4 VCL CAV1 ACTB ROCK1 KTN1 FLNA+ CALR DNA FBLIM1 CORO1B RAC1 + replication +ACTN1 ITGA6 + Met4 ITGAV Parkinson ITGB1 disease Actin cytoskel.
    [Show full text]
  • Tubulin in Platelets: When the Shape Matters
    International Journal of Molecular Sciences Review Tubulin in Platelets: When the Shape Matters Ernesto José Cuenca-Zamora 1 , Francisca Ferrer-Marín 1,2,*, José Rivera 1 and Raúl Teruel-Montoya 1 1 Servicio de Hematología y Oncología Médica, Centro Regional de Hemodonación, Hospital Universitario Morales Meseguer, IMIB-Arrixaca, Red CIBERER CB15/00055, 30003 Murcia, Spain 2 Grado de Medicina, Universidad Católica San Antonio (UCAM), Campus de los Jerónimos, 30107 Murcia, Spain * Correspondence: ff[email protected]; Tel.: +34-968-341990 Received: 1 May 2019; Accepted: 17 June 2019; Published: 16 July 2019 Abstract: Platelets are anuclear cells with a short lifespan that play an essential role in many pathophysiological processes, including haemostasis, inflammation, infection, vascular integrity, and metastasis. Billions of platelets are produced daily from megakaryocytes (platelet precursors). Despite this high production, the number of circulating platelets is stable and, under resting conditions, they maintain their typical discoid shape thanks to cytoskeleton proteins. The activation of platelets is associated with dynamic and rapid changes in the cytoskeleton. Two cytoskeletal polymer systems exist in megakaryocytes and platelets: actin filaments and microtubules, based on actin, and α- and β-tubulin heterodimers, respectively. Herein, we will focus on platelet-specific tubulins and their alterations and role of the microtubules skeleton in platelet formation (thrombopoiesis). During this process, microtubules mediate elongation
    [Show full text]
  • Original Article Plasma CAMK2A Predicts Chemotherapy Resistance in Metastatic Triple Negative Breast Cancer
    Int J Clin Exp Pathol 2018;11(2):650-663 www.ijcep.com /ISSN:1936-2625/IJCEP0069558 Original Article Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer Bin Shao1*, Zhihua Tian2*, Huirong Ding2*, Qingsong Wang3, Guohong Song1, Lijun Di1, Hong Zhang2, Huiping Li1, Jing Shen2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), 1Department of Medical Oncology, 2Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, P. R. China; 3State Key Laboratory of Protein and Plant Gene Research, College of Life Sciences, Peking University, Beijing, P. R. China. *Equal contributors. Received November 21, 2017; Accepted December 15, 2017; Epub February 1, 2018; Published February 15, 2018 Abstract: Background: Chemotherapy resistance is a great obstacle in effective treatment for metastatic triple nega- tive breast cancer (TNBC). The ability to predict chemotherapy response would allow chemotherapy administration to be directed toward only those patients who would benefit, thus maximizing treatment efficiency. Differentially expressed plasma proteins may serve as putative biomarkers for predicting chemotherapy outcomes. Patients and methods: In this study, 26 plasma samples (10 samples with partial response (S) and 16 samples with progression disease (R)) from patients with metastatic TNBC were measured by Tandem Mass Tag (TMT)-based proteomics analysis to identify differentially expressed proteins between the S and R group. Potential proteinswere validated with enzyme-linked immunosorbent assay (ELISA) in another 67 plasma samples. Results: A total of 320 plasma proteins were identified, and statistical analysis showed that 108 proteins were significantly dysregulated between R and S groups in the screening stage. Bioinformatics revealed relevant pathways and regulatory networks of the differentially expressed proteins.
    [Show full text]
  • The Case of Meat Color from Charolais Breed Mohammed Gagaoua, Muriel Bonnet, Leanne De Koning, Brigitte Picard
    Reverse phase protein array for the quantification and validation of protein biomarkers of beef qualities: The case of meat color from Charolais breed Mohammed Gagaoua, Muriel Bonnet, Leanne de Koning, Brigitte Picard To cite this version: Mohammed Gagaoua, Muriel Bonnet, Leanne de Koning, Brigitte Picard. Reverse phase protein array for the quantification and validation of protein biomarkers of beef qualities: The case of meat colorfrom Charolais breed. Meat Science, Elsevier, 2018, 145 (C), pp.308-319. 10.1016/j.meatsci.2018.06.039. hal-01860004 HAL Id: hal-01860004 https://hal.archives-ouvertes.fr/hal-01860004 Submitted on 22 Aug 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Meat Science 145 (2018) 308–319 Contents lists available at ScienceDirect Meat Science journal homepage: www.elsevier.com/locate/meatsci Reverse Phase Protein array for the quantification and validation of protein biomarkers of beef qualities: The case of meat color from Charolais breed T ⁎ Mohammed Gagaouaa, , Muriel Bonneta, Leanne De Koningb, Brigitte Picarda a INRA, Université Clermont Auvergne, VetAgro Sup, UMR Herbivores, Saint-Genès-Champanelle F-63122, France b Institut Curie centre de recherche, Université de recherche PSL Plateforme RPPA, 26 rue de l'UlM, Paris 75248, France ARTICLE INFO ABSTRACT Keywords: Reverse Phase Protein Arrays (RPPA) were applied for the quantification and validation of protein biomarkers of Biomarkers beef qualities on M.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Proteomic Expression Profile in Human Temporomandibular Joint
    diagnostics Article Proteomic Expression Profile in Human Temporomandibular Joint Dysfunction Andrea Duarte Doetzer 1,*, Roberto Hirochi Herai 1 , Marília Afonso Rabelo Buzalaf 2 and Paula Cristina Trevilatto 1 1 Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil; [email protected] (R.H.H.); [email protected] (P.C.T.) 2 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-41-991-864-747 Abstract: Temporomandibular joint dysfunction (TMD) is a multifactorial condition that impairs human’s health and quality of life. Its etiology is still a challenge due to its complex development and the great number of different conditions it comprises. One of the most common forms of TMD is anterior disc displacement without reduction (DDWoR) and other TMDs with distinct origins are condylar hyperplasia (CH) and mandibular dislocation (MD). Thus, the aim of this study is to identify the protein expression profile of synovial fluid and the temporomandibular joint disc of patients diagnosed with DDWoR, CH and MD. Synovial fluid and a fraction of the temporomandibular joint disc were collected from nine patients diagnosed with DDWoR (n = 3), CH (n = 4) and MD (n = 2). Samples were subjected to label-free nLC-MS/MS for proteomic data extraction, and then bioinformatics analysis were conducted for protein identification and functional annotation. The three Citation: Doetzer, A.D.; Herai, R.H.; TMD conditions showed different protein expression profiles, and novel proteins were identified Buzalaf, M.A.R.; Trevilatto, P.C.
    [Show full text]
  • Protein Network Analyses of Pulmonary Endothelial Cells In
    www.nature.com/scientificreports OPEN Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension Sarath Babu Nukala1,8,9*, Olga Tura‑Ceide3,4,5,9, Giancarlo Aldini1, Valérie F. E. D. Smolders2,3, Isabel Blanco3,4, Victor I. Peinado3,4, Manuel Castell6, Joan Albert Barber3,4, Alessandra Altomare1, Giovanna Baron1, Marina Carini1, Marta Cascante2,7,9 & Alfonsina D’Amato1,9* Chronic thromboembolic pulmonary hypertension (CTEPH) is a vascular disease characterized by the presence of organized thromboembolic material in pulmonary arteries leading to increased vascular resistance, heart failure and death. Dysfunction of endothelial cells is involved in CTEPH. The present study describes for the frst time the molecular processes underlying endothelial dysfunction in the development of the CTEPH. The advanced analytical approach and the protein network analyses of patient derived CTEPH endothelial cells allowed the quantitation of 3258 proteins. The 673 diferentially regulated proteins were associated with functional and disease protein network modules. The protein network analyses resulted in the characterization of dysregulated pathways associated with endothelial dysfunction, such as mitochondrial dysfunction, oxidative phosphorylation, sirtuin signaling, infammatory response, oxidative stress and fatty acid metabolism related pathways. In addition, the quantifcation of advanced oxidation protein products, total protein carbonyl content, and intracellular reactive oxygen species resulted increased
    [Show full text]
  • Pflugers Final
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Serveur académique lausannois A comprehensive analysis of gene expression profiles in distal parts of the mouse renal tubule. Sylvain Pradervand2, Annie Mercier Zuber1, Gabriel Centeno1, Olivier Bonny1,3,4 and Dmitri Firsov1,4 1 - Department of Pharmacology and Toxicology, University of Lausanne, 1005 Lausanne, Switzerland 2 - DNA Array Facility, University of Lausanne, 1015 Lausanne, Switzerland 3 - Service of Nephrology, Lausanne University Hospital, 1005 Lausanne, Switzerland 4 – these two authors have equally contributed to the study to whom correspondence should be addressed: Dmitri FIRSOV Department of Pharmacology and Toxicology, University of Lausanne, 27 rue du Bugnon, 1005 Lausanne, Switzerland Phone: ++ 41-216925406 Fax: ++ 41-216925355 e-mail: [email protected] and Olivier BONNY Department of Pharmacology and Toxicology, University of Lausanne, 27 rue du Bugnon, 1005 Lausanne, Switzerland Phone: ++ 41-216925417 Fax: ++ 41-216925355 e-mail: [email protected] 1 Abstract The distal parts of the renal tubule play a critical role in maintaining homeostasis of extracellular fluids. In this review, we present an in-depth analysis of microarray-based gene expression profiles available for microdissected mouse distal nephron segments, i.e., the distal convoluted tubule (DCT) and the connecting tubule (CNT), and for the cortical portion of the collecting duct (CCD) (Zuber et al., 2009). Classification of expressed transcripts in 14 major functional gene categories demonstrated that all principal proteins involved in maintaining of salt and water balance are represented by highly abundant transcripts. However, a significant number of transcripts belonging, for instance, to categories of G protein-coupled receptors (GPCR) or serine-threonine kinases exhibit high expression levels but remain unassigned to a specific renal function.
    [Show full text]
  • Thrombocytopenia-Associated Mutations in Ser/Thr Kinase MASTL
    Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeleton dynamics in platelets by Begoña Hurtado et al. SUPPLEMENTARY MATERIAL List of Supplementary Figures Figure S1. Hematopoietic precursors and megakaryocytes maturation in Mastl mutant mice. Figure S2. Sialylation and apoptosis profile of Mastl mutant platelets. Figure S3. Mastl E166D activity results in increased phosphorylation levels. Figure S4. Phospho-proteomic analysis in Mastl mutant platelets after thrombin activation. Figure S5. Signaling pathways differentially phosphorylated in Mastl mutant platelets. Figure S6. Changes in the phosphorylation status of signaling molecules in Mastl-mutant platelets. Figure S7. Full scan of blots showed in the manuscript. List of Supplementary Tables Table S1. Full data from phospho-proteomic studies. 1 Table S2. KEGG pathways enriched (FDR>0.05) in hyperphosphorylated proteins in resting Mastl(ED/ED) platelets (log2FC ED/WT>0.75), considering as statistical background the mouse platelet proteome. Table S3. KEGG pathways enriched (FDR>0.05) in hypophosphorylated proteins in resting Mastl(/) platelets (log2FC/WT<0.75), considering as statistical background the mouse platelet proteome. Table S4. KEGG pathways enriched (FDR>0.01) in hyperphosphorylated proteins in Mastl(ED/ED) platelets 3 minutes after stimulation with thrombin (log2FC ED/WT>0.75). Table S5. KEGG pathways enriched (FDR>0.01) in hyperphosphorylated proteins in both resting and 3-min-activated Mastl(ED/ED) platelets (log2FC ED/WT>0.5), considering as statistical background the mouse platelet proteome. Table S6. KEGG pathways enriched (FDR>0.05) in hyperphosphorylated proteins in Mastl(ED/ED) platelets 15 minutes after stimulation with thrombin (log2FC ED/WT>1.0), considering as statistical background the mouse platelet proteome.
    [Show full text]
  • Neurobiology of Axonal Transport Defects in Motor Neuron Diseases: Opportunities for Translational Research?
    Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Article (Published Version) De Vos, Kurt J and Hafezparast, Majid (2017) Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiology of Disease, 105. pp. 283- 299. ISSN 0969-9961 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/66929/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. http://sro.sussex.ac.uk YNBDI-03908; No. of pages: 17; 4C: 3 Neurobiology of Disease xxx (2017) xxx–xxx Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Kurt J.
    [Show full text]
  • Thrombocytopenia: an Australasian Perspective ISTH Advanced Training Course
    Genetic Testing in Inherited Thrombocytopenia: An Australasian Perspective ISTH Advanced Training Course Presented By: Dr David Rabbolini 7th September 2016 ISTH Advanced Training Course Dubai, UAE Disclosures for David Rabbolini In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research Support/P.I. No relevant conflicts of interest to declare Employee No relevant conflicts of interest to declare Consultant No relevant conflicts of interest to declare Major Stockholder No relevant conflicts of interest to declare Speakers Bureau No relevant conflicts of interest to declare Honoraria No relevant conflicts of interest to declare Scientific Advisory No relevant conflicts of interest to declare Board Presentation includes discussion of the following off-label use of a drug or medical device: <N/A> ISTH Advanced Training Course Dubai, UAE - 2 - Outline . Introduction . Traditional phenotypic testing approach . Genetic testing – rationale . Our experience using a candidate gene panel . Observations from inherited platelet disorders caused by transcription factor mutation. Concluding remarks ISTH Advanced Training Course Dubai, UAE - 3 - Inherited platelet disorders . Uncommon conditions . True prevalence is likely underestimated . Under recognised . Many lack a preceding family history . MYH9-RDs – 20-30% de novo mutations. Variable bleeding tendencies. Not all present in childhood. Savoia A., et al., Journal of Thrombosis and ISTHHaemostasis Advanced Training, 2010. Course Balduini CL., et al., Journal of Thrombosis and HaemostasisDubai, UAE , 2013. Diagnosis is of importance . Prevent potentially futile and harmful treatments . Many inherited thrombocytopenias are diagnosed as ITP ~20% . Predisposition to other illnesses . RUNX1 (FPD/AML) – Acute myelid leukaemia. ETV6 and EVI1 – Solid organ and haematological malignancies. MYH9-RDs – renal failure, cataracts, sensorineural deafness.
    [Show full text]
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression
    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
    [Show full text]